Why did shares in Hikma Pharmaceuticals plc and GlaxoSmithKline plc crash last week?

Shares in GlaxoSmithKline plc (LON: GSK) and Hikma Pharmaceuticals plc (LON: HIK) are crashing but should you sell?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the beginning of October, shares in GlaxoSmithKline(LSE: GSK) and Hikma (LSE: HIK) have been on the retreat. After a rally during the first six months of the year (shares in Glaxo and Hikma rose 20% and 15% respectively in H1), since the beginning of October Glaxo has lost approximately 7% and Hikma is down 20%. 

This sell-off accelerated last week. Over the past seven days, shares in Hikma have lost 6% and Glaxo’s shares are down by 4%, both exceeding the FTSE 100’s decline of 2.3% over the same period. 

The big question is, what’s the reason for these declines and will they continue? 

Pharma falling out of favour 

One of the developments that could be to blame for the recent declines is the buzz around the US election. Healthcare reform has been a key debating point among all candidates since the beginning of campaigning. There’s a fear among investors, especially over in the US, that the incoming president could force companies to lower their drug prices, decimating profitability. These concerns have sent the shares in major US pharmaceutical companies plunging. During the past two months, the SPDR S&P Pharmaceuticals ETF has dropped by 18%. 

Alongside election concerns, shares in Glaxo and Hikma have come under pressure from a stronger pound. When the value of sterling plunged, their shares jumped as weak sterling means higher profits. But a stronger sterling will erase some FX-induced profit boost, and with profits set to come in lower than expected, it makes perfect sense that the shares would fall. Since the beginning of November, sterling has strengthened by around 3%-4%. 

Still attractive 

Glaxo and Hikma may have fallen out of favour with investors during the past few weeks, but these companies remain attractive long-term investments. 

City analysts expect Hikma’s earnings per share to fall by 24% this year due to one-off effects, before rebounding by 35% during 2017 as the company’s revenue and profitability hits an all-time high. Based on 2017 forecasts, shares in the company are currently trading at a forward P/E of 13.8, which looks cheap for a fast-growing defensive company like Hikma.

City analysts expect Glaxo’s earnings per share to jump by 31% this year and a further 9% during 2017 as the company benefits from a weaker sterling and organic growth. What’s more, management has stated that the firm’s 80p share dividend payout is here to stay for the foreseeable future, so that market-leading yield of 5.2% isn’t at risk in the near term.

The bottom line 

So overall, it would appear that shares in Glaxo and Hikma dropped last week due to outlook concerns. However, for the time being, the outlook for these companies remains bright and after recent declines, the shares trade at extremely attractive valuations. For the long-term investor then, now might be the time to buy Glaxo and Hikma on weakness. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Should I follow Warren Buffett and sell my favourite shares?

Billionaire US investor Warren Buffett has been selling tons of Apple shares and other stocks of businesses he thinks are…

Read more »

Investing Articles

As like-for-like sales continue to fall, is the B&M European Value Retail SA (LSE:BME) share price a bargain?

B&M European Value Retail is known for its low prices, but could growing like-for-like sales make the share price the…

Read more »

Illustration of flames over a black background
Investing Articles

After rocketing 232% in a year can this red-hot FTSE 250 stock keep going gangbusters?

Harvey Jones says this FTSE 250 stock's on fire after smashing the index over the last year. It's cheaper than…

Read more »

Investing Articles

The Burberry share price has jumped 15% this morning! Time to pile in?

Harvey Jones was thrilled to wake up this morning and find the Burberry share price flying, but he's still sitting…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

At a bargain-basement price now, is it time for me to buy this 8%-yielding FTSE 250 media stock?

Shares in this FTSE 250 broadcasting firm continued their recent decline after the latest results release, leaving them looking an…

Read more »